Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medtronic Collaboration with Mpirik to Address Disparities in Care Associated with Sudden Cardiac Arrest

09/13/2021 | 10:00am EDT

Medtronic plc announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac arrest (SCA), a condition in which the heart suddenly and unexpectedly stops beating. SCA is caused by a disturbance in the heart's electrical system, and can be deadly if not treated by defibrillation within minutes. Globally, cardiac arrest claims more lives than colorectal cancer, breast cancer, prostate cancer, influenza, pneumonia, auto accidents, HIV, firearms, and house fires combined.1 Proven treatment options include implantable cardioverter defibrillators (ICDs) or cardiac resynchronization therapy-defibrillators (CRT-Ds), established therapies that have been in use for more than 30 years. However, Medtronic-sponsored research has shown that patients who are medically indicated for these implantable heart devices often do not receive them. Recent studies have shown treatment disparities tied to gender and race: women and men of color, along with white women, receive devices at lower rates than white men. The Medtronic collaboration with Mpirik also involves Vizient, a health care performance improvement organization that provides data and analytic insights. This pilot program aims to identify patients at higher risk for SCA, and identify them earlier in their care journey. Mpirik's proprietary artificial intelligence platform, Cardiac Intelligence®, will screen electronic health records (EHRs) data at five pilot hospitals, including three Vizient member hospitals, to spot patients, regardless of race or gender, who meet prespecified clinical criteria for being at risk of SCA. Mpirik will provide an automated alert through the EHR system for these patients, enabling clinicians to determine appropriate follow-up care. The identification process will continue to protect patient health information, none of which will be shared with Medtronic or Vizient. ICDs deliver lifesaving shocks or painless pacing to stop life-threatening fast or irregular heartbeats that can lead to SCA. Cardiac resynchronization therapy is a treatment for heart failure that uses an implantable CRT device to improve the pumping efficiency of the heart; the device can be a CRT-pacemaker (CRT-P) or CRT-defibrillator (CRT-D). Typically, these devices are implanted by electrophysiologists, cardiologists who specialize in identifying and treating heart rhythm disorders, after patients are referred by general practitioners or general cardiologists.


ę S&P Capital IQ 2021
All news about MEDTRONIC PLC
10/26Titan medical announces completion of pre-clinical glp studies
AQ
10/25Aziyo Biologics, Inc. Announces Termination of FiberCel Distribution Agreement with Med..
CI
10/25MEDTRONIC : Canada announces commercial launch of Mazor™ X, the first dedicated robo..
AQ
10/22MEDTRONIC : Austin L. Chiang, M.D., M.P.H. joins Medtronic as Chief Medical Officer for Ga..
AQ
10/21Austin L. Chiang, M.D., M.P.H. Joins Medtronic as Chief Medical Officer for Gastrointes..
CI
10/19MEDTRONIC : Children achieve Time in Range mirroring well-controlled adults for the first ..
PR
10/19Medtronic plc Announces Children achieve Time in Range mirroring well-controlled adults..
CI
10/18MEDTRONIC : Shares Down Midday After DSMB Recommends Continued Enrollment of Symplicity Tr..
MT
10/18MEDTRONIC : Wells Fargo Adjusts Price Taget on Medtronic to $144 from $151, Keeps Overweig..
MT
10/18Medtronic Plc Down Over 5%, On Pace for Largest Percent Decrease Since June 2020 -- Dat..
DJ
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 990 M - -
Net income 2022 5 614 M - -
Net Debt 2022 20 291 M - -
P/E ratio 2022 30,9x
Yield 2022 1,96%
Capitalization 165 B 165 B -
EV / Sales 2022 5,61x
EV / Sales 2023 5,27x
Nbr of Employees 90 000
Free-Float 99,7%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Last Close Price 122,50 $
Average target price 145,52 $
Spread / Average Target 18,8%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Clinical & Regulatory Officer, Senior VP
Richard E. Kuntz Chief Medical & Scientific Officer, Senior VP
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC4.58%164 862
ABBOTT LABORATORIES16.64%226 407
BECTON, DICKINSON AND COMPANY-2.09%70 362
HOYA CORPORATION21.16%56 045
DEXCOM, INC.51.07%54 038
SARTORIUS STEDIM BIOTECH61.88%50 358